Medipharm Labs Corp's stock has seen a modest decline this week amid broader market movements.
Medipharm Labs Corp (LABS.TO) closed at C$0.08 on Friday, with a 1-day performance of 0.00% and a weekly decline of 6.25%. Investors are closely monitoring the company's recent developments and financial performance as it navigates the evolving cannabis market.
Investor takeaway: Despite the recent price fluctuations, Medipharm Labs Corp's long-term outlook remains positive, driven by its recent revenue growth and expansion plans.
Advertisement
Medipharm Labs Corp
LABS.TO
LABS.TO
Medipharm Labs Corp
WealthAwesomeMarket cap
$32.04M
52W high
$0.10
52W low
$0.06
1W change
+0.00%
Beta
0.93
Analyst Price Targets
Based on analyst covering LABS
Wall Street analysts forecast LABS stock price to rise 33.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.10
+33.3% Upside
Current Price
C$0.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LABS's historical volatility
30-Day Vol
88.1%
Annualized
90-Day Vol
84.5%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.08
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.06 โ C$0.10 |
| 60 trading days | C$0.08 | C$0.05 โ C$0.12 |
| 90 trading days | C$0.08 | C$0.04 โ C$0.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
The company reported an 8% annual revenue growth and a significant 43% increase in international medical cannabis revenue, showing strong demand and potential for future profitability.
Bear case
However, the stock is currently trading near the lower end of its 52-week range. Persistent losses, indicated by negative profit margins and return on equity, could discourage some investors.
Price Action Overview
Medipharm Labs Corp's stock closed at C$0.08 on Friday, maintaining a stable price but reflecting a weekly decline of 6.25%. Year-to-date, the stock has gained 7.14%, suggesting some resilience despite recent volatility.
Advertisement
Recent Company Developments
While there were no significant press releases this week, the company has recently reported financial results showcasing an 8% increase in annual revenue and a notable 43% rise in international medical cannabis revenue. This growth aligns with the company's strategic focus on expanding its footprint in the international market.
Technical Picture
From a technical standpoint, Medipharm Labs is currently trading at the 50-day moving average of C$0.07, indicating a positive trend of 7.1% versus its current price. The 200-day moving average also stands at C$0.07, suggesting a longer-term bullish outlook of 11.9%. The stock's 52-week range is between C$0.06 and C$0.10, with a beta of 0.92, indicating lower volatility compared to the market. The latest trading volume of 42,808 shares is below the 20-day average of 221,456 shares, reflecting reduced trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
